Pfizer has made a decisive move to reestablish itself in the obesity therapeutics market by acquiring Metsera for $4.9 billion upfront, with additional milestones potentially bringing the deal’s total value to $7.3 billion. The acquisition includes Metsera's pipeline of oral and injectable GLP-1 receptor agonists and combination therapies aimed at delivering improved dosing convenience and efficacy. This strategic buyout follows Pfizer's earlier withdrawal from obesity drug development and comes amid growing competition in this space from companies like Eli Lilly and Novo Nordisk. Key upcoming Phase 2 data readouts for Metsera’s lead candidate are expected in 2026, bolstering Pfizer’s ambitions in cardiometabolic diseases.